Nuvation Bio Inc. (NUVB)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | 4,833 | 3,084 | 727 | |
| Cost of revenue | 2,576 | 2,094 | 1,515 | |
| Gross profit | 2,257 | 990 | -788 | |
| Selling, general and administrative | 38,484 | 35,393 | 19,582 | |
| Research and development | 27,362 | 24,601 | 27,731 | |
| Acquired in-process research and development | - | - | - | |
| Total operating expenses | 65,846 | 59,994 | 47,313 | |
| Loss from operations | -63,589 | -59,004 | -48,101 | |
| Investment advisory fees | 182 | 203 | 237 | |
| Other (expense) income | -14 | 1,452 | - | |
| Realized (loss) gain on marketable securities | -1 | 3 | -11 | |
| Interest income | 4,780 | 5,321 | 6,726 | |
| Interest expense | 421 | 54 | 120 | |
| Net loss on disposal of fixed assets | -34 | - | - | |
| Change in fair value of warrant liability | -454 | 751 | -533 | |
| Total other income (expense), net | 4,582 | 5,768 | 6,891 | |
| Loss before income taxes | -59,007 | -53,236 | -41,210 | |
| Provision for income taxes | - | - | - | |
| Net loss | -59,007 | -53,236 | -41,210 | |
| Change in unrealized loss on available-for-sale securities | -225 | -493 | - | |
| Currency translation adjustment | 646 | -465 | - | |
| Comprehensive loss | -59,878 | -53,264 | -41,210 | |
| Net loss per share attributable to common stockholders, basic | -0.17 | -0.16 | -0.15 | |
| Net loss per share attributable to common stockholders, diluted | -0.17 | -0.16 | -0.15 | |
| Weighted average common shares outstanding, basic | 340,746 | 338,612 | 273,565 | |
| Weighted average common shares outstanding, diluted | 340,746 | 338,612 | 273,565 | |